Advertisement

Expert Highlights RESPONSE Results With Ruxolitinib in Polycythemia vera

Long-term follow-up data from the ongoing phase III RESPONSE trial, released at the 2017 American Society of Hematology Annual Meeting, show continued safety and response of ruxolitinib in patients with polycythemia vera resistant or intolerant to hydroxyurea.

 OncLive